Observational studyScientific reports2025
Elevated serum CA72-4 as a novel diagnostic biomarker for acute gout flares.
Observational study in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While Glycoantigen 724 (CA72-4) is well-established as a tumor marker, its association with gout has yet to be fully explored. Our study aimed to investigate the expression levels of CA72-4 and other tumor markers at different stages of gout in patients and to assess any changes in their expression levels following treatment with colchicine. For this observational clinical study, participants with gout were recruited and divided into two groups: a gout-flare group and a gout-no-flare group. Additionally, healthy volunteers were recruited as controls. The clinical characteristics of the three groups were compared, and the ROC curve was used to compare the diagnostic value of C-reactive protein (CRP) and CA72-4 for gout flare. Gout flare is divided into two subgroups: a group receiving colchicine and a group receiving without colchicine; comparing the clinical characteristics of the two groups. Serum CA72-4 levels were significantly higher in gout flare compared to gout no flare and healthy controls (P < 0.01). There was no significant difference regarding other tumor markers (Glycoantigen 125 (CA12-5), Glycoantigen 199 (CA19-9), and Carcinoembryonic antigen (CEA)) among the various groups. Elevated levels of CA72-4 and CRP, BMI, and tophi were independent correlates of acute gout attacks (OR = 1.438, 95% CI: 1.240 ~ 1.668, P < 0.01; OR = 1.533, 95% CI: 1.282～1.834, P < 0.01; OR = 3.368, 95% CI: 1.229～9.230, P = 0.018; OR = 1.451, 95% CI: 1.020～2.064, P = 0.038). ROC curve analysis showed that CA72-4 had a higher area under the curve compared to CRP (AUC = 0.966, 95% CI: 0.944～0.981, P < 0.01; AUC = 0.900, 95% CI: 0.867～0.927, P < 0.01). However, serum CA72-4 levels were further elevated during gout flare in the group receiving colchicine (P < 0.01). During gout flare, serum CA72-4 levels were significantly elevated. Serum CA72-4 and CRP can be considered diagnostic serum markers for the acute phase of gout. Colchicine can cause further elevation of serum CA72-4 in gouty flares.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.